Floatz logo

Ast-201

Advanced Ovarian Cancer

Aston Sci. Inc.vaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

524 Active assets in the Advanced Ovarian Cancer cohort.

Asset / SponsorPhaseRating
TIL
Inge Marie Svane
Phase 2BB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
Olaparib
Shandong University
Phase 4BB
OTL-38
On Target Laboratories, LLC
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Kalinski, Pawel, MD, PhD
Phase 3BB

View all 50 →

Same molecule, other indications

Ast-201 is also rated in:

liver and intrahepatic bile duct neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
neoplasmDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →